1. Search Result
Search Result
Results for "

management

" in MCE Product Catalog:

26

Inhibitors & Agonists

1

Screening Libraries

3

Peptides

3

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-100129
    JNJ-17203212

    TRP Channel Neurological Disease
    JNJ-17203212 is a selective, potent and competitive TRPV1 antagonist. JNJ-17203212 is developed for researching pain management, such as migraine.
  • HY-N2127
    Pinostrobin

    Ser/Thr Protease Inflammation/Immunology
    Pinostrobin is a flavonoid can be found in many plants, and has anti-oxidant, anti-inflammatory, anti-cancer and neuroprotective properties. Pinostrobin is a potent PCSK9 inhibitor and inhibits the catalytic activity of PCSK9. Pinostrobin is a promising agent for cholesterol regulation and lipid management.
  • HY-B0191
    Bimatoprost

    AGN 192024

    Prostaglandin Receptor Endocrinology
    Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.
  • HY-14286
    Levosimendan

    Simsndan; OR-1259

    Potassium Channel Phosphodiesterase (PDE) Autophagy Cardiovascular Disease
    Levosimendan (Simsndan; OR-1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.
  • HY-17359
    Deferasirox

    ICL 670

    Bacterial Ferroptosis Cancer
    Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload.
  • HY-107917
    Desoxycorticosterone pivalate

    DOCP

    Others Endocrinology
    Desoxycorticosterone pivalate (DOCP) is a mineralocorticoid hormone and an analog of Desoxycorticosterone. Desoxycorticosterone pivalate is used for the management of canine hypoadrenocorticism.
  • HY-B2165
    Bendazac L-Lysine

    Others Others
    Bendazac L-Lysine is one of agents that have been introduced for the management of cataracts, protecting the level of vision in patients, thus delaying the need for surgical intervention.
  • HY-14286S
    Levosimendan D3

    Simsndan D3; OR-1259 D3

    Potassium Channel Phosphodiesterase (PDE) Autophagy Cardiovascular Disease
    Levosimendan D3 (Simsndan D3) is a deuterium labeled Levosimendan. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.
  • HY-B0100
    Etomidate

    R 16659

    GABA Receptor Neurological Disease
    Etomidate (R 16659) is a potent GABAA receptor agonist. Etomidate is a neurological drug and effective parenteral medication and has the potential for management of endogenous hypercortisolaemia.
  • HY-B2008
    Famoxadone

    DPX-JE874

    Fungal Infection
    Famoxadone (DPX-JE874) is a fungicide acting against a broad spectrum of fungi and is widely used in Integrated Pest Management strategies in different agricultural crops.
  • HY-B0100A
    Etomidate hydrochloride

    R16659 hydrochloride

    GABA Receptor Neurological Disease
    Etomidate hydrochloride (R 16659 hydrochloride) is a potent GABAA receptor agonist. Etomidate hydrochlorideis a neurological drug and effective parenteral medication and has the potential for management of endogenous hypercortisolaemia.
  • HY-10003
    Alfacalcidol

    1-hydroxycholecalciferol; 1.alpha.-Hydroxyvitamin D3

    VD/VDR Metabolic Disease
    Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis.
  • HY-W050000
    OR-1855

    Potassium Channel Phosphodiesterase (PDE) Autophagy Cardiovascular Disease
    OR-1855, an active metabolite of Levosimendan, has effect on human myometrial contractility. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.
  • HY-N1362
    Salvianolic acid B

    Lithospermic acid B

    Autophagy Cardiovascular Disease
    Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.
  • HY-B1107
    Naftidrofuryl oxalate

    Nafronyl oxalate salt

    5-HT Receptor Cardiovascular Disease
    Naftidrofuryl oxalate (Nafronyl oxalate salt) is a drug used in the management of peripheral and cerebral vascular disorders as a vasodilator, enhance cellular oxidative capacity, and may also be a 5-HT2 receptor antagonist.
  • HY-17429
    Flecainide acetate

    R-818

    Sodium Channel Cardiovascular Disease
    Flecainide acetate (R-818) is a class 1C antiarrhythmic drug especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential.
  • HY-13693
    Mometasone furoate

    Sch32088

    Glucocorticoid Receptor Inflammation/Immunology Endocrinology
    Mometasone furoate (Sch32088) is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic activity. Mometasone furoate acts as a corticosteroid agent and used for topical applications in chronic skin eczema and airway inflammation management of asthma in vivo
  • HY-132131
    Vazegepant hydrochloride

    Zavegepant hydrochloride; BHV-3500 hydrochloride

    CGRP Receptor Infection Inflammation/Immunology
    Vazegepant (BHV-3500) hydrochloride is a highly soluble CGRP receptor antagonist (hCGRP Ki= 0.023 nM). Vazegepant hydrochloride is the first intranasal gepant for migraine. Vazegepant hydrochloride may be helpful in effective management of COVID-19 associated pulmonary inflammation.
  • HY-14263
    Pericyazine

    Propericiazine; RP 8909

    Dopamine Receptor Neurological Disease
    Pericyazine (Propericiazine) is a first-generation antipsychotic agent that is used as an adjunct to the short-term management of severe anxiety states and psychosis. Pericyazine is a selective D2-dopamine receptor antagonist. Pericyazine has adrenolytic, anticholinergic, and extrapyramidal effects.
  • HY-P1812
    AUNP-12

    NP-12

    PD-1/PD-L1 Cancer
    AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
  • HY-14263S
    Pericyazine-d4

    Dopamine Receptor Neurological Disease
    Pericyazine-d4 (Propericiazine-d4) is the deuterium labeled Pericyazine. Pericyazine (Propericiazine) is a first-generation antipsychotic agent that is used as an adjunct to the short-term management of severe anxiety states and psychosis. Pericyazine is a selective D2-dopamine receptor antagonist. Pericyazine has adrenolytic, anticholinergic, and extrapyramidal effects.
  • HY-P1812A
    AUNP-12 TFA

    NP-12 TFA

    PD-1/PD-L1 Cancer
    AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
  • HY-N0407
    Picroside I

    6'-Cinnamoylcatalpol

    STAT Inflammation/Immunology
    Picroside I is the major ingredient of Picrorhiza kurroa. Picrorhiza kurroa is a high value medicinal herb due to rich source of hepatoprotective metabolites, Picroside-I and Picroside-II. Picroside I is a promising agent for the management of asthma. Picroside I reduces the inflammation significantly at its higher dose. Picroside I also downregulates pSTAT6 and GATA3 expressions. Picroside I dose-dependently increases the serum levels of IFN-γ.
  • HY-B0563
    Ropivacaine

    Sodium Channel Potassium Channel Neurological Disease Cardiovascular Disease
    Ropivacain is a potent sodium channel blocker and acts as a local anesthetic agent. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. Ropivacaine is used for the research of regional anesthesia and neuropathic pain management.
  • HY-B0563B
    Ropivacaine hydrochloride

    Sodium Channel Potassium Channel Neurological Disease Cardiovascular Disease
    Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. Ropivacaine is a local anesthetic agent widely used for regional anesthesia and neuropathic pain management in vivo.
  • HY-B0563A
    Ropivacaine hydrochloride monohydrate

    Sodium Channel Potassium Channel Neurological Disease Cardiovascular Disease
    Ropivacaine hydrochloride monohydrate is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. Ropivacaine is a local anesthetic agent widely used for regional anesthesia and neuropathic pain management in vivo.